Biohackers Gear Up for Genome Editing
By Heidi Ledford,
Nature News
| 08. 26. 2015
Untitled Document
A complete lack of formal scientific training has not kept Johan Sosa from dabbling with one of the most powerful molecular-biology tools to come along in decades.
Sosa has already used CRISPR, a three-year-old technology that makes targeted modifications to DNA, in test-tube experiments. Next week, he hopes to try the method in yeast and, later, in the model plant Arabidopsis thaliana.
Hailed for its simplicity and versatility, CRISPR allows scientists to make specific changes to a gene’s sequence more easily than ever before. Researchers have used CRISPR to edit genes in everything from bacteria to human embryos; the technique holds the potential to erase genetic defects from family pedigrees plagued by inherited disease, treat cancer in unprecedented ways or grow human organs in pigs. One researcher has even proposed modifying the elephant genome to produce a cold-adapted replica of the long-extinct woolly mammoth.
Such feats are beyond the reach of do-it-yourself (DIY) ‘biohackers’, a growing community of amateur biologists who often work in community laboratories, which typically charge a recurring fee for...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...
By Staff, The Medicine Maker | 03.21.2025
"The Promise and Peril of CRISPR" cover by Johns Hopkins University Press
As a paediatrician taking care of children with sickle cell disease, Neal Baer, a Harvard Medical School graduate, was in awe of the power of CRISPR technologies. Later...